Global Biopharmaceuticals Market 2023-2030

Global Biopharmaceuticals Market 2023-2030

Global Biopharmaceuticals Market Size, Share & Trends Analysis Report by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Vaccines, Hormones, Gene Therapies and Others), by Service (Laboratory Testing, Customer Proprietary Testing, Compendial and Multi Compendial Laboratory Testing), and by Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Cardiovascular Diseases, Neurological Diseases and Other), Forecast Period (2023-2030)

Global biopharmaceuticals market is anticipated to grow at a CAGR of 7.2 % during the forecast period (2023-2030). Chronic diseases such as cancer, autoimmune disorders, diabetes, and cardiovascular diseases continue to rise globally. Biopharmaceutical consumption globally growing, partly driven by a growing need for drugs to treat aging-related and chronic diseases. The growing adoption of technological advancement for drug discovery in complex diseases is the key factor supporting the growth of the market globally. According to the World Health Organization (WHO), in August 2023, HPV infection caused about 5.0% of all cancers globally, with an estimated 625 600 women and 69 400 men getting HPV-related cancer each year. Women living with human immunodeficiency virus (HIV) are six times more likely to develop cervical cancer compared to women without HIV. Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced stages. Market players are continuously focusing on the introduction of drugs for chronic diseases. For instance, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Segmental Outlook

The global biopharmaceuticals market is segmented by product type, service, and application. Based on the product type, the market is sub-segmented into monoclonal antibodies, recombinant growth factors, purified proteins, vaccines, hormones, gene therapies, and others (interferon, synthetic immunomodulators). Based on the service, the market is sub-segmented into laboratory testing, customer proprietary testing, and compendial and multi-compendial laboratory testing. Further, based on application, the market is sub-segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, cardiovascular diseases, neurological diseases, and other (hormonal disorders). Among the applications, the oncology sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of oncology drugs including a wide range of medications such as targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies to treat cancer.

The Vaccines Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biopharmaceuticals Market

Among the product types, the vaccines sub-segment is expected to hold a considerable share of the global biopharmaceutical market. The segmental growth is attributed to an increase in the integration of nanotechnology, gene-based assays, next-generation sequencing technologies, and genetic engineering in the process of vaccine development is expected to enhance the revolutionary potential of novel vaccine types. Nucleic acid vaccines, mRNA vaccines, vector vaccines, and biomaterial-based vaccines are recent trends in the revolutionization of vaccines based on their potential to address issues of existing technology. For instance, in September 2023, Pfizer Inc. and BioNTech SE announced that the US FDA approved the supplemental biologics license application for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.

Regional Outlook

The global biopharmaceuticals market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to a strong base of healthcare facilities, and the availability of advanced treatment options that specifically target the underlying causes of these complex diseases, improved therapeutic outcomes, and enhanced patient care in this region.

The North American region is Expected to Grow at a Significant CAGR in the Global Biopharmaceuticals Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to a rise in the adoption and availability of biopharmaceuticals for disease treatment and a surge in disease diagnosis awareness. Demand for local and imported pharmaceutical products increased as economies grew, and healthcare provision and insurance mechanisms expanded. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in May 2022, in 2021 North America accounted for 49.1% of global pharmaceutical sales compared with 23.4% for Europe. the diversity of pharmaceutical needs as emerging markets increasingly address noncommunicable diseases (NCDs) already prevalent in stronger economies, including diabetes and hypertension, while communicable diseases that afflict many emerging markets such as acquired immunodeficiency syndrome, malaria, and tuberculosis persist. The increase in the global population is also contributing to pharmaceutical consumption.

The market growth is driven by various factors, such as an increase in the elderly population, a surge in the prevalence of chronic diseases such as cancer and diabetes, and an increase in the adoption of biopharmaceuticals globally. Furthermore, a rise in strategic collaborations among biopharmaceutical companies is also anticipated to supplement the growth of the biopharmaceutical industry. The key market player includes AbbVie Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Pfizer Inc. and others.

Market Players Outlook

The major companies serving the biopharmaceuticals market include F. Hoffmann-La Roche AG, Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, IAVI, a nonprofit scientific research organization addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, Darmstadt, Germany, a science and technology company, to develop COVID-19 neutralizing monoclonal antibodies (mAbs).

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global biopharmaceuticals market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.